Due to the compounds plasma half-life of approximately 3.86.9 hours, twice-daily (BID) dosing may provide more sustained NNMT inhibition
ProHealth BPC-157 is a dietary supplement, not an FDA-approved drug
However, because AOD-9604 does not affect appetite or insulin sensitivity, having breakfast immediately after administration does not appear to interfere with the peptides fat tissue effects, making timing more flexible than with compounds that rely on specific insulin or glucose states
Regulatory Status Disclaimer Semaglutide, tirzepatide, PT-141, and thymosin alpha 1 have regulatory approval in at least one country for at least one indication
The commenter stated that CMS already uses other programs, such HACRP, to incentivize safety improvement and that layering additional reputational penalties may duplicate or conflict with existing incentives
TA-1 is one of the more clinically credible peptides on this list, and it has a pretty great safety profile